CATHLEEN CASSIE: Open Payments
NPI 1588220966 · AUGUSTA, ME. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,952 in 45 payments from 14 companies in 2025. Trend: 2023 $1,281 · 2024 $800 · 2025 $1,952
Food & beverage: $1,248Travel & lodging: $705
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation | 4 | $1,014 |
| Gilead Sciences, Inc. | 6 | $211 |
| ABBVIE INC. | 11 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $137 |
| Madrigal Pharmaceuticals | 3 | $74 |
| Janssen Biotech, Inc. | 3 | $74 |
| Ipsen Biopharmaceuticals, Inc | 2 | $61 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 2 | $46 |
| Lilly USA, LLC | 2 | $33 |
Products named: General - Therapies, Livdelzi, ENTYVIO, RINVOQ, REZDIFFRA, TREMFYA, IQIRVO, XIFAXAN.
Industry payments across ME — which companies pay providers there.
